HNHiroshi Nagata

Hiroshi Nagata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroshi Nagata has a total of 189 co-authors. Here are the top co-authors by number of shared publications:

  • Hiroaki Nozawa

    Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    12 shared publications
  • Kazushige Kawai

    Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    11 shared publications
  • Soichiro Ishihara

    Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    10 shared publications
  • Toshiaki Tanaka

    Department of Surgical Oncology, the University of Tokyo, Tokyo, Japan

    10 shared publications
  • Keisuke Hata

    Department of Surgical Oncology, University of Tokyo , Tokyo , Japan

    9 shared publications
  • Takeshi Nishikawa

    Department of Surgical Oncology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    6 shared publications

Latest Publications

  • Open Access

    Preoperative Computed Tomography Colonography‐Angiography for Vascular Mapping to Guide and Standardize D3 Lymphadenectomy in Right‐Sided and Transverse Colon Cancer

    by Takeharu Kato, Yukihide Kanemitsu, Mototaka Miyake, Gen Tomizawa, Kohei Takura, Hiroshi Nagata, Yasuyuki Takamizawa, Konosuke Moritani, Shunsuke Tsukamoto

    Background: In right hemicolectomy (RHC) and left‐sided transverse colectomy (TC), D3 lymph node dissection is oncologically significant but technically demanding because of marked vascular variability. Standardization requires reliable preoperative anatomical assessment. We evaluated colic vascular anatomy and quantified D3 dissection distance using computed tomography colonography‐angiography (CTC‐A). Methods: We retrospectively analyzed 591 patients with primary right or transverse colon cancer who underwent preoperative CTC‐A during 2014–2023. Arterial origins, venous drainage, and positional relationships around the superior mesenteric artery (SMA) and vein (SMV) were classified. After excluding aberrant cases, branching patterns relevant to D3 dissection were categorized and D3 distances measured along the SMA centerline using curved planar reformation images. Results: An accessory middle colic artery (aMCA) was present in 38.1% of patients (SMA‐derived, 76.4%). The MCA originated as a common trunk in 77.8% and as independent branches in 19.0%. The right colic artery (RCA) was observed in 41.8%. Four reproducible vascular patterns each were identified for RHC and TC. In RHC ( n = 490), independent‐origin MCA was consistently associated with shorter D3 distances (RCA‐present, 22.5 vs. 27.5 mm, p = 0.012; RCA‐absent, 16.5 vs. 20.5 mm, p < 0.001). In TC ( n = 524), the aMCA originated dorsal to the pancreas in ~23%, and D3 distance was shorter in aMCAs with an independent‐origin MCA (18.0 vs. 25.0 mm, p < 0.001). Conclusions: High‐resolution CTC‐A yielded a single‐modality, operation‐oriented mapping integrating tumor location with mesenteric arteriovenous anatomy. Pattern‐based classification and objective D3 distance estimation may support preoperative planning and help establish standardized, safer D3 lymphadenectomy for right‐sided and transverse colon cancer.


  • Open Access

    The R.O.A.D. to clinical trial emulation

    by Georgios Antonios Margonis, Dimitris Bertsimas, Angelos Koulouras, Hiroshi Nagata, Carol Gao, Junki Mizusawa, Yukihide Kanemitsu

    Observational studies provide the only evidence on the effectiveness of interventions when randomized controlled trials (RCTs) - apart from the initial RCT that establishes the efficacy of a treatment compared to a placebo - are impractical due to cost, ethical concerns, or time constraints. While many methodologies aim to draw causal inferences from observational data, there is a growing trend to model observational study designs after hypothetical or existing RCTs, a strategy known as “target trial emulation.” Despite its potential, causal inference through target trial emulation is challenging because it cannot fully address the confounding bias inherent in real-world data due to the lack of randomization. In this work, we present a novel framework for target trial emulation that aims to overcome several key limitations, including confounding bias. The framework proceeds as follows: First, we apply the eligibility criteria of a specific trial to an observational cohort derived from real-world data. We then “correct” this cohort by extracting a subset that, through optimization techniques, matches both the distribution of covariates and baseline prognoses (i.e., the prognosis in the trial’s control group) of the target RCT. Next, we address unmeasured confounding by adjusting the prognosis estimates of the treated group to align with those observed in the trial, using cost-sensitive counterfactual models. Following trial emulation, we go a step further by leveraging the emulated cohort to train optimal decision trees, developed by our team, to identify subgroups of patients exhibiting heterogeneity in treatment effects (HTE). The absence of confounding is verified using two external models, and the validity of the treatment effects estimated by our framework is independently confirmed by the team responsible for the original trial we emulate. To our knowledge, this is the first framework to successfully address both observed and unobserved confounding, a challenge that has historically limited the use of randomized trial emulation and causal inference in general since the 1950s. Additionally, our framework holds promise in advancing precision or personalized medicine by identifying patient subgroups that benefit most from specific treatments.


  • Open Access

    A Non-Invasive Deep Photoablation Technique to Inhibit DCIS Progression and Induce Antitumor Immunity

    by Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, et al.

    Ductal carcinoma in situ (DCIS) of the breast is often managed by lumpectomy and radiation or mastectomy, despite its indolent features. Effective non-invasive treatment strategies could reduce the morbidity of DCIS treatment. We have exploited the high heat shock protein 90 (HSP90) activity in premalignant and malignant breast disease to non-invasively detect and selectively ablate tumors using photodynamic therapy (PDT). PDT with the HSP90-targeting photosensitizer, HS201, can not only ablate invasive breast cancers (BCs) while sparing non-tumor tissue, but also induce antitumor immunity. We hypothesized that HS201-PDT would both non-invasively ablate DCIS and prevent progression to invasive BC. We tested in vitro selective uptake and photosensitivity of HS201 in DCIS cell lines compared to the non-selective parental verteporfin, and assessed in vivo antitumor efficacy in mammary fat pad and intraductal implantation models. Selective uptake of HS201 enabled treatment of intraductal lesions while minimizing toxicity to non-tumor tissue. The in vivo activity of HS201-PDT was also tested in female MMTV-neu mice prior to the development of spontaneous invasive BC. Mice aged 5 months were administered HS201, and their mammary glands were exposed to laser light. HS201-PDT delayed the emergence of invasive BC, significantly prolonged disease-free survival (DFS) (p = 0.0328) and tended to improve overall survival compared to the no-treatment control (p = 0.0872). Systemic administration of anti-PD-L1 was combined with HS201-PDT and was tested in a more aggressive spontaneous tumor model, HER2delta16 transgenic mice. A single PDT dose combined with anti-PD-L1 improved DFS compared to the no-treatment control, which was significantly improved with repetitive HS201-PDT given with anti-PD-L1 (p = 0.0319). In conclusion, a non-invasive, skin- and tissue-sparing PDT strategy in combination with anti-PD-L1 antibodies effectively prevented malignant progression of DCIS to invasive BC. This non-invasive treatment strategy of DCIS may be safe and effective, while providing an option to reduce the morbidity of current conventional treatment for patients with DCIS. Clinical testing of HS201 is currently underway.


  • Laparoscopic Colectomy: A Risk Factor for Postoperative Peritoneal Metastasis

    by Hiroshi Nagata, Kazushige Kawai, Koji Oba, Hiroaki Nozawa, Shinichi Yamauchi, Kenichi Sugihara, Soichiro Ishihara


  • Open Access

    The Characteristics of 206 Long-Term Survivors with Peritoneal Metastases from Colorectal Cancer Treated with Curative Intent Surgery: A Multi-Center Cohort from PSOGI

    by Yasuyuki Kamada, Koya Hida, Yutaka Yonemura, Paul H. Sugarbaker, Shadin Ghabra, Soichiro Ishihara, Hiroshi Nagata, Koji Murono, Takanori Goi, Kanji Katayama, et al.

    Background: We conducted this study to review the patient characteristics associated with long-term survival in patients with peritoneal metastases from colorectal cancer who underwent cytoreductive surgery (CRS). Methods: We retrospectively investigated patients with peritoneal metastases from CRC treated with curative intent surgery with or without hyperthermic intraperitoneal chemotherapy at 13 institutions worldwide between January 1985 and April 2015 and survived longer than five years after the first CRS for peritoneal metastases. Clinical and oncological features and therapeutic parameters were described and analyzed. Results: Two hundred six long-term survivors were available for study. The median peritoneal cancer index (PCI) of this cohort was 4 (interquartile range (IQR), 2–7), and the median score of the small bowel regions of the PCI (SB-PCI) was 0 (IQR, 0–2). Complete cytoreduction (CC-0) was achieved in 180 (87.4%) patients. Recurrence was observed in 122 (59.2%) patients at a median of 1.8 (IQR, 1.2–2.6) years. Conclusions: While most long-term survivors showed low PCI/SB-PCI and CCR-0, some had characteristics considered associated with poor prognosis. Curative intent treatments may be considered in well-informed and fit patients showing negative factors affecting survival outcome.


  • Laparoscopic surgery for T4 colon cancer: a risk factor for peritoneal recurrences?

    by Hiroshi Nagata, Kazushige Kawai, Keisuke Hata, Toshiaki Tanaka, Hiroaki Nozawa, Soichiro Ishihara


  • Development and Validation of a Prediction Model for Organ-Specific Recurrences After Curative Resection of Colon Cancer

    by Hiroshi Nagata, Soichiro Ishihara, Koji Oba, Toshiaki Tanaka, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa

    BACKGROUND: Early detection of postoperative recurrence is beneficial for patients with cancer; however, optimal surveillance remains an issue. To optimize the follow-up plan, the estimation of an individual patient’s risk of recurrence is indispensable.OBJECTIVE: This study aimed to establish a statistical model for predicting the risk of organ-specific recurrence after curative resection of colon cancer.DESIGN: This was a retrospective cohort study at a tertiary referral hospital.SETTINGS: This study included 1720 patients with colon cancer treated at the University of Tokyo Hospital between 1997 and 2015. Data were retrospectively retrieved from patient medical charts. The risk score was developed using a competing risk model in a derivation cohort (973 patients treated in 1997–2009) and then validated in a validation cohort (747 patients treated in 2010–2015).PATIENTS: Patients who underwent curative resection for stage I to III colon cancer were included.MAIN OUTCOME MEASURES: The prediction of the incidence of postoperative liver and lung metastasis of colon cancer was measured.RESULTS: The factors selected for the prediction model for liver metastasis included differentiation, T category, venous invasion, N category, and preoperative CEA level. The model for lung metastasis included sex, lymphatic invasion, venous invasion, N category, preoperative CEA level, and malignant bowel obstruction. During external validation, the area under the curve at 60 months was 0.78 (95% CI, 0.71–0.84) for liver metastasis and 0.72 (95% CI, 0.64–0.81) for lung metastasis.LIMITATIONS: The generalizability of the model to different healthcare settings remains to be elucidated.CONCLUSIONS: We developed a prediction model to estimate the risk of recurrence in the liver and lung after curative resection of colon cancer, which demonstrated good discrimination ability in the external validation cohort. Our model can aid clinicians and patients in customizing postoperative surveillance according to an individual patient’s risk of organ-specific recurrence. SeeVideo Abstractat http://links.lww.com/DCR/A977.DESARROLLO Y VALIDACIÓN DE UN MODELO DE PREDICCIÓN PARA RECURRENCIAS ESPECÍFICAS DESPUÉS DE RESECCIÓN CURATIVA DE UN CÁNCER DE COLON: ANTECEDENTES:La detección temprana de una recidiva postoperatoria es beneficiosa para los pacientes afectados de cáncer. Sin embargo, la mejor vigilancia sigue siendo un problema. Para optimizar el plan de seguimiento, la estimación del riesgo individual de recurrencia de un paciente es indispensable.OBJETIVO: Establecer un modelo estadístico para predecir el riesgo de recurrencia en un organo específico luego de la resección curativa de un cáncer de colon.DISEÑO: Estudio retrospectivo de cohortes en un hospital de referencia terciaria.AJUSTES: Este estudio incluyó 1720 pacientes con cáncer de colon tratados en el Hospital de la Universidad de Tokio entre 1997 y 2015. Los datos se recuperaron retrospectivamente de las historias clinicas de los pacientes. La puntuación de riesgo fué desarrollada utilizando un modelo de riesgo competitivo en cohortes de derivación (973 pacientes tratados en 1997–2009) y luego se lo validó en cohortes de validación (747 pacientes tratados en 2010–2015).PACIENTES: Todos aquellos casos que se sometieron a una resección curativa de cáncer de colon en estadio I-IIIRESULTADOS PRINCIPLES: La predicción de la incidencia de metástasis hepáticas y pulmonares postoperatorias del cáncer de colon.RESULTADOS: Los factores seleccionados para el modelo de predicción de metástasis hepáticas incluyeron diferenciación tumoral, categoría T, invasión venosa, categoría N y nivel de antígeno carcinoembrionario preoperatorio. El modelo de predicción de metástasis pulmonar incluyó el sexo del paciente, la invasión linfática, la invasión venosa, la categoría N, el nivel de antígeno carcinoembrionario preoperatorio y la obstrucción intestinal maligna. Durante la validación externa, el área inferior de la curva a 60 meses fue de 0,78 (intervalo de confianza del 95%: 0,71 a 0,84) para las metástasis hepáticas y de 0,72 (intervalo de confianza del 95%: 0,64 a 0,81) para las metástasis pulmonares.LIMITACIONES: La generalización del presente modelo a diferentes entornos de atención en salud aún no ha podido ser dilucidado.CONCLUSIONES: Desarrollamos un modelo de predicción para estimar el riesgo de recurrencia en el hígado y el pulmón después de resección curativa de cáncer de colon, éste modelo demostró una buena capacidad de discriminación en las cohortes de validación externa. El modelo puede ayudar a médicos y pacientes a personalizar la vigilancia postoperatoria de acuerdo con el riesgo individual de recurrencia específica en un órgano específico. Vea el Resumen del Video en http://links.lww.com/DCR/A977.


  • Gene Expression Signature in Surgical Tissues and Endoscopic Biopsies Identifies High-Risk T1 Colorectal Cancers

    by Raju Kandimalla, Tsuyoshi Ozawa, Feng Gao, Xin Wang, Ajay Goel, Hiroaki Nozawa, Keisuke Hata, Hiroshi Nagata, Satoshi Okada, Toshiaki Watanabe, et al.


  • Open Access

    LGR5 expression predicts peritoneal recurrence after curative resection of primary colon cancer

    by Hiroshi Nagata, Soichiro Ishihara, Hiroyuki Abe, Tetsuo Ushiku, Junko Kishikawa, Toshiaki Tanaka, Keisuke Hata, Kazushige Kawai, Masashi Fukayama, Hiroaki Nozawa

    Background The aim of this study was to clarify whether a cancer stem cell marker could be an indicator of post-operative peritoneal recurrence of colon cancer. Methods Expression of four putative markers (CD133, CD44 variant 6, aldehyde dehydrogenase-1 and leucine-rich repeating G-protein-coupled receptor-5 (LGR5)) was evaluated immunohistochemically in primary tumour samples from 292 patients who underwent curative resection for non-metastasised pT4 colon cancer at the University of Tokyo Hospital between 1997 and 2015. Results Peritoneal recurrence was significantly higher in LGR5-negative cases (5-year cumulative incidence: 27.5% vs. 14.4%, p = 0.037). Multivariable analysis confirmed that negative LGR5 expression was an independent risk factor for peritoneal recurrence (hazard ratio (HR) 2.79, p = 0.005) in addition to poor differentiation, positive lymph node metastasis, preoperative carcinoembryonic antigen > 5 ng/mL and anastomotic leakage. The addition of LGR5 significantly improved the predictive value of the multivariable model (net reclassification improvement: 0.186, p = 0.028: integrated discrimination improvement: 0.047, p = 0.008). Conclusions Negative LGR5 expression was a significant predictor of peritoneal recurrence in patients with pT4 colon cancer. Therefore, LGR5 might be a promising biomarker to identify patients at high risk of post-operative peritoneal metastasis.


  • Prognostic significance of doubling time in patients undergoing radical surgery for metachronous peritoneal metastases of colorectal cancer

    by Hiroaki Miyake, Koji Murono, Hiroshi Nagata, Hiroaki Nozawa, Kazushige Kawai, Keisuke Hata, Toshiaki Tanaka, Takeshi Nishikawa, Yasutaka Shuno, Kazuhito Sasaki, et al.

    The doubling times of tumor volume and tumor markers are associated with the prognosis of liver or lung metastases from colorectal cancer (CRC). However, no studies have assessed peritoneal metastases. Therefore, we aimed to elucidate the association between doubling time and the prognosis of patients who underwent radical surgery for metachronous peritoneal metastases of CRC.